Sanyou Bio and BioGeometry Join Forces to Develop AI-Powered Antibody Drug Discovery Platform
Friday, July 12, 2024
BioGeometry and Sanyou Bio have announced a strategic partnership to advance drug research and development. BioGeometry, known for its AI-driven protein design, and Sanyou Bio, a leader in innovative biologic drug R&D, will utilize their strengths in generative AI and drug development to create a next-generation antibody discovery platform. This collaboration aims to foster cooperation with leading pharmaceutical companies, enhancing global competitiveness.
Sanyou Bio will integrate BioGeometry's generative AI antibody design platform, GeoBiologics, into its operations. Both companies will pool their resources, technologies, and expertise to develop an advanced Dry-Wet antibody R&D platform. This will combine BioGeometry's AI algorithms with Sanyou Bio's laboratory capabilities, facilitating the development of large molecule drugs and innovative projects.
Sanyou Bio has established a high-throughput R&D platform for antibody drugs, featuring the world's largest antibody library with a capacity of up to 10 trillion. This platform integrates phage display and mammalian cell protein expression technologies, along with fully automated screening and R&D capabilities. It is designed to address challenging targets and develop high-affinity, highly developable molecules.
BioGeometry has developed atomic-level geometric deep learning models that accelerate antibody design and reduce costs. Their generative AI antibody discovery SaaS platform, GeoBiologics, combines AI design with high-throughput laboratory validation, enhancing prediction accuracy and efficiency through iterative AI and experimental feedback.
Sanyou Bio, stated, "BioGeometry's AI technology has revolutionized our antibody drug R&D platform, enhancing our drug discovery capabilities. Our collaboration with BioGeometry will accelerate preclinical research and facilitate clinical trials, improving the global competitiveness of pharmaceutical R&D."
BioGeometry, added, "We are excited to collaborate with Sanyou Bio to create an AI-enabled antibody discovery platform. This platform will set a new standard in AI-empowered drug R&D, accelerating antibody drug development and contributing to global disease treatment."
Source: prnewswire.com
